Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus tegafur for advanced colorectal cancer
ChiCTR1800018800Phase 4Not yet recruiting
- Sponsor
- Army Specialized Medical Center
- Start
- Nov 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and tegafur in colorectal cancer (CRC), sponsored by Army Specialized Medical Center. Primary endpoint: progression-free survival. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
Rivoceranibtegafur
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1800018800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018800.